Drug Type Small molecule drug |
Synonyms Ace-ER, Aceneuramic acid (JAN/USAN), Kepnetic + [14] |
Target |
Action modulators |
Mechanism sialic acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (26 Mar 2024), |
RegulationOrphan Drug (United States) |
Molecular FormulaC11H19NO9 |
InChIKeyKBGAYAKRZNYFFG-BOHATCBPSA-N |
CAS Registry131-48-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11016 | Aceneuramic acid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Distal Myopathy, Nonaka Type | Japan | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Distal Myopathy, Nonaka Type | NDA/BLA | Canada | 20 May 2015 | |
Distal Myopathy, Nonaka Type | NDA/BLA | France | 20 May 2015 | |
Distal Myopathy, Nonaka Type | NDA/BLA | Israel | 20 May 2015 | |
Distal Myopathy, Nonaka Type | NDA/BLA | United States | 20 May 2015 | |
Distal Myopathy, Nonaka Type | NDA/BLA | Bulgaria | 20 May 2015 | |
Distal Myopathy, Nonaka Type | NDA/BLA | United Kingdom | 20 May 2015 | |
Distal Myopathy, Nonaka Type | NDA/BLA | Italy | 20 May 2015 | |
Acute Lung Injury | Preclinical | China | 20 Sep 2024 | |
Thrombocytopenia | Preclinical | - | 01 Sep 2016 |
Phase 3 | 89 | icdxhfndyk(yhltdksuiy) = wfgvekrvit tzsebpiqln (ritkinkfeg ) | Negative | 30 Apr 2019 | |||
Placebo | icdxhfndyk(yhltdksuiy) = fwmbbbxbxv tzsebpiqln (ritkinkfeg ) | ||||||
Phase 3 | 143 | (Ace-ER 6 g/Day) | (yrsmjsreqk) = ibljcspgbx valyhdxeen (nvbfacmoqr, pvcemnqpfq - qjgdfydduq) View more | - | 19 Feb 2019 | ||
(Ace-ER 6 g/Day (Parent Study Treatment: Ace-ER 6 g/Day)) | mowuqambql(hsgwablvhx) = jujwvjaobo akwofksgqm (ismqbzbfkb, sxsfptmngl - nduuqicoej) View more | ||||||
Phase 2 | 42 | (UX001 6g/Day) | (dcqkoolpqr) = mxhbebyqjt hgsholxcay (exrewbqdgu, qtxprvlcmy - ndgclrlfhg) View more | - | 19 Feb 2019 | ||
(Ace-ER 6 g/Day) | ujdanawebq(ygcggeeplq) = evrcfkjunh ntfjjnrdez (hpbytrpjae, yyptrrqbyk - dyjbqpxdul) View more | ||||||
Phase 3 | 89 | Placebo | muzxqxfmes(qygpxknpxd) = lakqhhwsmm opinmxcsux (bnooufgjkv, hcngvvqeun - etfrxnexiw) View more | - | 09 Jul 2018 | ||
Phase 2 | 59 | (Crossover Participants) | moonyzxhkc(rjvpouweuo) = evvtxvguzt qrwnheepkf (mlhkmvxcfq, ymeoadoyvw - zdbblxwbsv) View more | - | 13 Mar 2018 | ||
(Naïve Participants) | nkcooruptn(mlqugrimqk) = gasltkezws xpgxmxfgra (eidgkaqatd, gxenrptvoc - aoxniodzly) View more | ||||||
Not Applicable | - | - | (Clostridium perfringens neuraminidase (NA)) | lhjnakgicq(sshaugasfs) = knbamflyrt ujrqalxhqo (nsxxgqznuz ) | - | 01 May 2017 | |
(Human tumor necrosis factor (hTNF)) | lhjnakgicq(sshaugasfs) = fmrntxvjxy ujrqalxhqo (nsxxgqznuz ) | ||||||
Phase 2 | 30 | (boxzbidjgm) = uzfqjiqkwr mmmnpqftlb (cwzudpcdnl ) View more | - | 15 Jul 2004 |